Volume 25, Number 5—May 2019
Dispatch
Population-Based Estimate of Melioidosis, Kenya
Table 1
Clinical summary of patients with positive Burkholderia pseudomallei isolates, Kilifi, Kenya, 2002–2014*
Year | Age/sex | Clinical features | Risk factors | Diagnosis† | Culture source | Antimicrobial sensitivity |
Days in hospital | Outcome | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
AMC | STX | TET | CAZ | IMI | ||||||||
2002 |
8 d/M |
Fever, jaundice, respiratory distress |
None identified |
Neonatal sepsis |
Blood |
S |
S |
S |
S |
S |
3 |
Died |
2008 |
7 d/M |
Respiratory distress |
None identified |
Severe pneumonia, neonatal sepsis |
Blood |
S |
S |
S |
S |
S |
3 |
Survived |
2010 |
3 y/F |
Fever, respiratory distress |
Near-drowning |
Severe pneumonia, septic shock |
Blood |
S |
S |
S |
S |
S |
6 |
Died |
2011 |
52 y/M |
Persistent fever and night sweats of unknown duration |
None identified |
Acute renal failure, meningitis |
Blood |
S |
S |
S |
S |
S |
5 |
Died |
2014 | 68 y/F | Fever, bilateral cervical neck swellings | Diabetes mellitus | Diabetes, cervical lymphadenitis | Pus swab | S | S | S | S | S | 40 | Survived |
*AMC, amoxicillin/clavulanic acid; CAZ, ceftazidime; IMI, imipenem; S, susceptible; STX, trimethoprim/sulfamethoxazole; TET, tetracycline.
†Diagnosis at time of admission.
Page created: April 17, 2019
Page updated: April 17, 2019
Page reviewed: April 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.